We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed

By LabMedica International staff writers
Posted on 05 Apr 2024

A groundbreaking diagnostic platform that delivers antibiotic susceptibility test (AST) results with unprecedented speed can become an important tool for healthcare professionals to manage bacteremia. More...

The LifeScale AST system from Affinity Biosensors (Santa Barbara, CA, USA) is a state-of-the-art diagnostic platform that rapidly identifies the most effective antibiotics for treating dangerous bloodstream infections. This revolutionary system enables healthcare professionals to make well-informed treatment decisions, enhancing patient recovery, minimizing treatment costs, and promoting responsible antibiotic use. The fully automated benchtop system utilizes unique microfluidic sensing to measure the masses of individual microbes at high throughput, facilitating rapid and precise evaluation of phenotypic response to antibiotics. It delivers accurate results for carbapenem-resistant and multi-drug-resistant organisms in less than five hours—substantially reducing the time required for selecting the most appropriate antibiotic therapies for patients.

Designed to fit seamlessly into existing clinical workflows, LifeScale AST features simple, chemistry-free sample preparation and processing, high throughput, and cost-effective operations. It also boasts room-temperature consumables storage and compatibility with existing organism identification systems. The system's user-friendly touchscreen interface automates the workflow, significantly reducing the minimal hands-on time required for technicians. It provides minimum inhibitory concentration (MIC) results as well as interpretive (SIR) results using CLSI or FDA breakpoints. The capability to process multiple samples simultaneously further enhances the system's utility in a clinical setting. Following the initial launch of the Gram-negative blood culture AST panel plans for additional AST tests are underway. The LifeScale AST system has now received clearance from the U.S. Food and Drug Administration (FDA).

"We are very proud of achieving FDA clearance for the LifeScale AST system,” said Dr. Ken Babcock, CEO of Affinity Biosensors. “This revolutionary technology has the potential to transform how infections associated with sepsis are treated. We are very grateful to our dedicated team and partners who have worked tirelessly to bring LifeScale AST to market. We are especially gratified to witness this performance borne out in our collaborations with healthcare institutions nationwide."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.